Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug Black Diamond Therapeutics reports promising ...
Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Black Diamond Therapeutics (BDTX – Research Report), retaining the ...
TD Cowen analyst Marc Frahm has maintained their bullish stance on BDTX stock, giving a Buy rating today. Marc Frahm’s rating is based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback